Lillynow expects fourth-quarter revenue to be about $13.5 billion. “While the U.S. incretin market grew 45% compared to the same quarter last year, our previous guidance had anticipated even ...
Lillynow expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.9 billion for Zepbound. That is much higher than a year earlier but Explore Our Brands ...
The Street is looking for revenues of $13.95 billion for the quarter. Lillynow expects approximately $3.5 billion for Mounjaro and $1.9 billion for Zepbound. In total, non-incretin revenue grew ...
Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss drugs like Zepbound and Novo Nordisk's Ozempic ...
Results that may be inaccessible to you are currently showing.